Medistim ASA (FRA:MD1) GF Value Rank: 10 (As of Jul. 31, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MD1 Medistim ASA FRA:MD1
99 GF Score
Price €20.50
GF Value €23.25
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA GF Value Rank?

Medistim ASA FRA:MD1 +0.49% 99 GF Value Rank is 10 as of Jul. 31, 2026, which is 100% above its 10-year median of 5.00. GuruFocus rates FRA:MD1 with a GF Score™ of 99/100 and a GF Value™ of €23.25 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Medistim ASA has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Medistim ASA GF Value Rank Related Terms

FRA:MD1 vs ABT, SYK, MDT: GF Value Rank Comparison

For the Medical Devices subindustry, Medistim ASA's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medistim ASA GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Medistim ASA's GF Value Rank falls into.


FRA:MD1
99GF Score
Medistim ASA FRA:MD1
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Medistim ASA (FRA:MD1) has a GF Value Rank of 10 as of Jul. 31, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Medistim ASA and its competitors. This is 100% above median its historical median of 5.00. Over the past decade, Medistim ASA's GF Value Rank has ranged from 1.00 to 10.00.
Is Medistim ASA's GF Value Rank too high?
Medistim ASA's current GF Value Rank of 10 is 100% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Medistim ASA has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's GF Value Rank compare to ABT and SYK?
Medistim ASA's GF Value Rank of 10 can be compared against companies in the Medical Devices & Instruments industry. Historically, Medistim ASA's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Medistim ASA and its competitors. Medistim ASA's current GF Value Rank is 10, which is 100% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Modestly Undervalued. The stock's GF Value™ is €23.25, compared to a current price of €20.50 — trading 11.8% below its estimated fair value. The current GF Value Rank is 10, which is 100% above median its 10-year median of 5.00. Medistim ASA's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current GF Value Rank is 10 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (FRA:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €20.50 is trading 11.8% below its estimated GF Value™ of €23.25. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for FRA:MD1:

  • GF Value Rank: 10 (100% above median its 10-year median of 5.00)
  • GF Value™: €23.25 vs. price of €20.50 (11.8% below fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
99GF Score

Get the complete analysis for FRA:MD1

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.50
Price
€23.25
GF Value